Back to Search
Start Over
Impact of Patients’ Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis
- Source :
- Clinical Genitourinary Cancer. 18:88-94.e2
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- Recent meta-analyses on checkpoint inhibitors in cancer report conflicting data regarding the association of patient gender with inhibitor efficacy. In advanced kidney cancer, checkpoint inhibitors have shown improved outcomes in first- and second-line settings compared with standard of care, but the role of patient gender on treatment outcome is unclear. We aimed to assess the efficacy of immunotherapy according to patient gender in advanced kidney cancer. We performed a systematic review and meta-analysis according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search was performed using PubMed, Scopus, Web of Science, and The Cochrane Library to identify eligible studies published through February 16, 2019. Studies were included if they reported on the differential outcomes of male and female patients with metastatic kidney cancer receiving immunotherapy. Our outcomes of interest were overall survival (OS) or progression-free survival (PFS). Four randomized controlled trials comprising a total of 3664 patients (2715 males and 949 females) met our inclusion criteria. Both men and women with metastatic kidney cancer had an OS and PFS advantage with immunotherapy compared with standard-of-care, but no statistically significant difference between the genders was observed (OS hazard ratio [HR] for men, 0.69; 95% confidence interval [CI], 0.59-0.8; P = .40; HR for women, 0.62; 95% CI, 0.48-0.81; P = .13; PFS HR for men, 0.7; 95% CI, 0.59-0.82; P = .24; HR for women, 0.68; 95% CI, 0.52-0.90; P = .105). In patients with advanced kidney cancer receiving checkpoint inhibitors, there seems to be no association of patient gender with treatment outcome.
- Subjects :
- Male
Oncology
medicine.medical_specialty
Urology
030232 urology & nephrology
Pembrolizumab
Cochrane Library
Kidney
law.invention
Avelumab
03 medical and health sciences
Sex Factors
0302 clinical medicine
Randomized controlled trial
law
Renal cell carcinoma
Internal medicine
medicine
Humans
Carcinoma, Renal Cell
Immune Checkpoint Inhibitors
Neoplasm Staging
business.industry
Cancer
Standard of Care
medicine.disease
Kidney Neoplasms
Progression-Free Survival
030220 oncology & carcinogenesis
Meta-analysis
Disease Progression
Female
business
Kidney cancer
medicine.drug
Subjects
Details
- ISSN :
- 15587673
- Volume :
- 18
- Database :
- OpenAIRE
- Journal :
- Clinical Genitourinary Cancer
- Accession number :
- edsair.doi.dedup.....a8e0de46a5e6662d2514b15391079212